22 March 2019
Clifford Chance advises Stallergenes on its takeover by Waypoint
International law firm Clifford Chance is advising the Special Committee of Directors of biopharmaceuticals group Stallergenes Greer (EPA: STAGR) in relation to the recommended acquisition of the company by its controlling shareholder Waypoint. The transaction, announced today, values the company at approximately €730 million.
Waypoint currently owns approximately 84% of the company. Upon completion of the acquisition, which will be implemented through a scheme of arrangement, the company will be de-listed from Euronext Paris.
The Clifford Chance team is led by Corporate Partners Joel Ziff (London), Gilles Lebreton and Aline Cardin (both Paris).